Ligand Pharmaceuticals (LGND) Short Interest Ratio & Short Volume $105.76 -3.43 (-3.14%) (As of 05:27 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Ligand Pharmaceuticals Short Interest DataLigand Pharmaceuticals (LGND) has a short interest of 812,800 shares. This marks a 3.45% increase in short interest from the previous month. The short interest ratio (days to cover) is 6.9, indicating that it would take 6.9 days of the average trading volume of 135,820 shares to cover all short positions.Current Short Interest812,800 sharesPrevious Short Interest785,700 sharesChange Vs. Previous Month+3.45%Dollar Volume Sold Short$95.02 millionShort Interest Ratio6.9 Days to CoverLast Record DateDecember 15, 2024Outstanding Shares18,895,000 sharesPercentage of Shares Shorted4.30%Today's Trading Volume139,293 sharesAverage Trading Volume135,820 sharesToday's Volume Vs. Average103% Short Selling Ligand Pharmaceuticals? Sign up to receive the latest short interest report for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartLGND Short Interest Over TimeLGND Days to Cover Over TimeLGND Percentage of Float Shorted Over Time Ad StocksToTradeliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the liberals broke”... But it turns out that was all just a smokescreen to hide the TRUTH…Click here to discover the real reason Elon Musk became buddy-buddy with Trump. Ligand Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 12/15/2024812,800 shares $95.02 million +3.5%N/A6.9 $116.91 11/30/2024785,700 shares $95.44 million -5.5%N/A7.1 $121.47 11/15/2024831,500 shares $92.89 million -9.5%N/A7.5 $111.71 10/31/2024918,600 shares $97.10 million -8.1%N/A8.5 $105.70 10/15/20241,000,000 shares $104.39 million +0.4%N/A9.5 $104.39 9/30/2024996,100 shares $99.70 million +1.9%N/A8.7 $100.09 Get the Latest News and Ratings for LGND and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 9/15/2024977,400 shares $102.40 million -1.8%N/A7.9 $104.77 8/31/2024995,000 shares $105.27 million -6.1%N/A8.1 $105.80 8/15/20241,060,000 shares $109.32 million +10.3%N/A8.3 $103.13 7/31/2024960,700 shares $104.71 million -12.7%N/A6.9 $108.99 7/15/20241,100,000 shares $106.34 million +17.7%N/A7.9 $96.67 6/30/2024934,400 shares $78.73 million -0.2%N/A6.5 $84.26 6/15/2024936,600 shares $74.98 million +32.3%N/A6.6 $80.06 5/31/2024707,700 shares $60.19 million -17.6%N/A4.3 $85.05 5/15/2024858,700 shares $73.65 million +7.9%N/A4.6 $85.77 4/30/2024795,600 shares $55.60 million -3.8%N/A4.3 $69.89 4/15/2024826,600 shares $65.94 million +23.0%5.0%4.9 $79.77 3/31/2024672,100 shares $49.13 million -23.3%4.1%4.1 $73.10 3/15/2024876,300 shares $62.30 million +14.9%5.3%5.8 $71.09 2/29/2024762,600 shares $60.51 million -15.0%4.6%5.3 $79.35 2/15/2024896,600 shares $66.93 million -3.6%5.5%7.3 $74.65 1/31/2024929,800 shares $67.97 million +1.0%5.7%8.1 $73.10 1/15/2024920,700 shares $66.84 million +2.2%6.9%8.2 $72.60 12/31/2023900,800 shares $64.34 million +0.8%5.5%8.2 $71.42 12/15/2023893,600 shares $60.18 million -1.7%5.5%8.1 $67.35 11/30/2023909,100 shares $53.01 million -2.3%5.5%8.8 $58.31 11/15/2023930,200 shares $52.54 million +6.1%5.7%9.2 $56.48 10/31/2023876,400 shares $45.83 million +3.8%5.4%8.8 $52.29 10/15/2023844,700 shares $46.45 million +2.5%5.2%8.8 $54.99 9/30/2023824,100 shares $49.38 million -0.1%5.1%8.4 $59.92 9/15/2023825,000 shares $51.13 million -6.2%5.1%8.8 $61.98 8/31/2023879,200 shares $57.82 million +4.6%5.4%9.1 $65.77 8/15/2023840,500 shares $56.81 million +4.3%5.2%8.6 $67.59 7/31/2023805,800 shares $53.93 million -3.4%5.0%8.2 $66.93 7/15/2023834,300 shares $56.61 million -1.4%5.1%8.4 $67.85 6/30/2023846,200 shares $61.01 million +4.0%5.2%8.6 $72.10 6/15/2023814,000 shares $64.30 million -1.6%5.0%7.8 $78.99 5/31/2023827,100 shares $57.96 million +1.3%5.1%7.9 $70.08 5/15/2023816,400 shares $63.34 million +0.7%5.0%7.2 $77.59 4/30/2023811,100 shares $61.93 million +5.1%5.1%7 $76.35liberals FOOLED by Elon’s shocking surprise (Ad)Elon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the liberals broke”... But it turns out that was all just a smokescreen to hide the TRUTH…Click here to discover the real reason Elon Musk became buddy-buddy with Trump. 4/15/2023771,800 shares $57.38 million -1.0%4.8%6.6 $74.34 3/31/2023779,200 shares $57.32 million -13.5%4.9%6.5 $73.56 3/15/2023900,500 shares $64.48 million +7.5%5.6%7.1 $71.61 2/28/2023838,100 shares $60.46 million +2.5%5.2%5.1 $72.14 2/15/2023817,900 shares $59.69 million +1.5%5.1%4.8 $72.98 1/31/2023806,000 shares $56.18 million +0.1%5.1%4.6 $69.70 1/15/2023805,000 shares $57.38 million +1.5%5.1%4.1 $71.28 12/30/2022792,800 shares $52.96 million -8.4%5.0%4.1 $66.80 12/15/2022865,800 shares $53.81 million +13.0%5.5%4.4 $62.15 11/30/2022766,100 shares $55.85 million -2.3%4.8%4.6 $72.90 11/15/2022784,100 shares $61.99 million +6.6%4.9%5 $79.06 10/31/2022735,400 shares $64.46 million -0.3%4.6%5 $87.65 10/15/2022737,800 shares $66.03 million -6.7%4.6%6 $89.49 9/30/2022790,600 shares $68.08 million -5.1%5.0%6.6 $86.11 9/15/2022833,000 shares $75.08 million +3.1%5.2%7 $90.13 8/31/2022808,200 shares $74.67 million -3.7%5.1%6.6 $92.39 8/15/2022839,000 shares $90.03 million -3.2%5.3%6.8 $107.31 7/31/2022866,700 shares $79.76 million -0.8%5.4%6.5 $92.03 7/15/2022873,600 shares $82.58 million -3.6%5.4%6 $94.53 6/30/2022905,800 shares $80.82 million -0.2%5.6%6 $89.22 6/15/2022907,900 shares $71.80 million -0.6%N/A5.7 $79.08 5/31/2022913,400 shares $81.21 million -10.5%5.7%6.2 $88.91 5/15/20221,020,000 shares $87.68 million -8.9%6.4%6.2 $85.96 4/30/20221,120,000 shares $104.00 million No Change7.0%6.8 $92.86 4/15/20221,120,000 shares $117.89 million -8.9%7.0%6.8 $105.26 3/31/20221,230,000 shares $138.36 million +2.5%7.7%7.2 $112.49 3/15/20221,200,000 shares $125.44 million -2.4%7.5%7.5 $104.53 2/28/20221,230,000 shares $124.50 million No Change7.7%7.7 $101.22 2/15/20221,230,000 shares $152.13 million -10.2%7.8%8.1 $123.68 1/31/20221,370,000 shares $170.74 million -11.0%8.6%9.7 $124.63 1/15/20221,540,000 shares $192.36 million -4.4%9.7%11.3 $124.91 12/31/20211,610,000 shares $248.68 million -4.2%10.1%13.4 $154.46 12/15/20211,680,000 shares $247.80 million +5.0%10.6%13.9 $147.50 11/30/20211,600,000 shares $259.07 million +0.6%10.1%13.5 $161.92 11/15/20211,590,000 shares $260.93 million -4.2%10.0%8 $164.11 10/29/20211,660,000 shares $242.26 million No Change10.5%8 $145.94 10/15/20211,660,000 shares $216.23 million -4.1%10.5%7.9 $130.26 9/30/20211,730,000 shares $241.02 million -2.8%10.9%8 $139.32 9/15/20211,780,000 shares $241.83 million +10.6%11.2%7.8 $135.86 8/31/20211,610,000 shares $213.00 million -0.6%10.2%7 $132.30 8/13/20211,620,000 shares $173.05 million -1.8%10.2%10.1 $106.82 7/30/20211,650,000 shares $187.29 million -6.3%10.4%11 $113.51 7/15/20211,760,000 shares $203.84 million +0.6%11.1%11.7 $115.82 6/30/20211,750,000 shares $229.58 million +1.7%11.0%11.7 $131.19 6/15/20211,720,000 shares $212.97 million +8.2%10.8%12 $123.82 5/28/20211,590,000 shares $187.14 million -0.6%10.0%9.8 $117.70 5/14/20211,600,000 shares $198.21 million -0.6%10.1%8.5 $123.88 4/30/20211,610,000 shares $234.69 million +2.6%10.1%6.1 $145.77 4/15/20211,570,000 shares $237.12 million +4.7%9.9%2.9 $151.03 3/31/20211,500,000 shares $223.67 million -19.4%9.5%2.6 $149.11liberals FOOLED by Elon’s shocking surprise (Ad)Elon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the liberals broke”... But it turns out that was all just a smokescreen to hide the TRUTH…Click here to discover the real reason Elon Musk became buddy-buddy with Trump. 3/15/20211,860,000 shares $306.49 million -15.8%11.8%3 $164.78 2/26/20212,210,000 shares $331.96 million -19.3%14.0%3.6 $150.21 2/12/20212,740,000 shares $493.31 million -54.1%17.9%4.5 $180.04 1/29/20215,970,000 shares $1.14 billion -40.4%38.9%10.3 $191.59 1/15/202110,010,000 shares $1.22 billion +1.0%64.9%21.5 $122.28 12/31/20209,910,000 shares $1.02 billion -0.7%64.2%28.9 $102.63 12/15/20209,980,000 shares $1.02 billion -1.6%64.7%29.5 $101.79 11/30/202010,140,000 shares $871.23 million -4.6%65.7%30.6 $85.92 11/15/202010,630,000 shares $889.84 million -1.0%68.9%32.7 $83.71 10/30/202010,740,000 shares $892.17 million +5.1%69.6%34.8 $83.07 10/15/202010,220,000 shares $1.02 billion +3.9%66.2%34.7 $100.01 9/30/20209,840,000 shares $937.95 million +6.0%63.8%39.7 $95.32 9/15/20209,280,000 shares $890.79 million +3.0%60.1%35 $95.99 8/31/20209,010,000 shares $919.02 million +0.9%58.4%34.6 $102.00 8/14/20208,930,000 shares $1.01 billion +4.6%57.9%31.6 $113.25 7/31/20208,540,000 shares $1.00 billion -3.3%55.5%27.5 $117.18 7/15/20208,830,000 shares $1.05 billion -1.9%57.3%26.7 $119.42 6/30/20209,000,000 shares $1.01 billion -4.8%58.3%24.6 $111.85 6/15/20209,450,000 shares $1.05 billion +2.1%61.2%22.3 $111.49 5/29/20209,260,000 shares $940.54 million -1.9%59.7%17.9 $101.57 5/15/20209,440,000 shares $932.20 million +2.8%60.9%16.8 $98.75 4/30/20209,180,000 shares $904.87 million -2.9%59.2%16.3 $98.57 4/15/20209,450,000 shares $835.19 million +2.2%59.7%17.1 $88.38 3/31/20209,250,000 shares $903.08 million +3.9%58.4%17.1 $97.63 3/13/20208,904,900 shares $769.56 million +12.6%56.1%14.1 $86.42 2/28/20207,910,000 shares $557.97 million +3.1%49.8%20.8 $70.54 2/14/20207,670,000 shares $752.58 million -0.1%45.4%24.4 $98.12 1/31/20207,680,000 shares $788.12 million -0.9%45.3%24.3 $102.62 1/15/20207,750,000 shares $734.39 million -0.3%45.7%23.8 $94.76 12/31/20197,770,000 shares $687.96 million +1.0%45.8%25 $88.54 LGND Short Interest - Frequently Asked Questions What is Ligand Pharmaceuticals' current short interest? Short interest is the volume of Ligand Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of December 15th, traders have sold 812,800 shares of LGND short. Learn More on Ligand Pharmaceuticals' current short interest. What is a good short interest ratio for Ligand Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LGND shares currently have a short interest ratio of 7.0. Learn More on Ligand Pharmaceuticals's short interest ratio. Which institutional investors are shorting Ligand Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Ligand Pharmaceuticals: Walleye Capital LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Ligand Pharmaceuticals' short interest increasing or decreasing? Ligand Pharmaceuticals saw a increase in short interest during the month of December. As of December 15th, there was short interest totaling 812,800 shares, an increase of 3.4% from the previous total of 785,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Ligand Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "biotechnology" compare to Ligand Pharmaceuticals: Repligen Co. (6.12%), Madrigal Pharmaceuticals, Inc. (21.69%), Halozyme Therapeutics, Inc. (6.98%), Ionis Pharmaceuticals, Inc. (7.23%), Alkermes plc (7.87%), Amicus Therapeutics, Inc. (6.56%), Geron Co. (10.67%), MannKind Co. (15.47%), Dynavax Technologies Co. (12.76%), Celldex Therapeutics, Inc. (11.02%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.32 billion), Spotify Technology S.A. ($4.06 billion), Canadian Natural Resources Limited ($3.45 billion), Reddit, Inc. ($2.79 billion), International Paper ($2.70 billion), Cencora, Inc. ($2.27 billion), SoFi Technologies, Inc. ($2.21 billion), Lululemon Athletica Inc. ($2.13 billion), and Rivian Automotive, Inc. ($2.05 billion). View all of the most shorted stocks. What does it mean to sell short Ligand Pharmaceuticals stock? Short selling LGND is an investing strategy that aims to generate trading profit from Ligand Pharmaceuticals as its price is falling. LGND shares are trading down $3.43 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Ligand Pharmaceuticals? A short squeeze for Ligand Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of LGND, which in turn drives the price of the stock up even further. How often is Ligand Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LGND, twice per month. The most recent reporting period available is December, 15 2024. More Short Interest Resources from MarketBeat Related Companies Repligen Short Interest Data Madrigal Pharmaceuticals Short Interest Data Halozyme Therapeutics Short Interest Data Ionis Pharmaceuticals Short Interest Data Alkermes Short Interest Data Amicus Therapeutics Short Interest Data Geron Short Interest Data MannKind Short Interest Data Dynavax Technologies Short Interest Data Celldex Therapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:LGND) was last updated on 12/30/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
